Interactions with CAB/RPV long acting injections
Pharmacokinetic interactions shown are mostly with RPV.
QT interactions shown are with RPV.
Interactions with Ibalizumab
None

Notes
a Co-administration is not recommended in the European labels, but the US labels suggest the following dose modifications:
When starting bosentan in individuals already on ritonavir or cobicistat containing regimens use a bosentan dose of 62.5 mg once daily or every other day.
Discontinue bosentan at least 36 h in prior to starting a ritonavir or cobicistat containing regimen and restart after at least 10 days at 62.5 mg once daily or every other day.
b If co-administration cannot be avoided, doravirine should be administered 100 mg twice daily (based on the interaction study with ritabutin, another moderate inducer) and maintained at this dose for at least another two weeks following cessation of the corticosteroid.
c Potential additive liver toxicity.
d Co-administration may decrease concentrations of bicalutamide; no effect on emtricitabine or tenofovir alafenamide is expected.
e Exposure of selexipag increased, but exposure of active metabolite unchanged.
f This change is unlikely to be clinically relevant.